

1 **Bronchoalveolar lavage metabolome dynamics reflect underlying disease and chronic** 2 **lung allograft dysfunction**

3
4 Christian Martin ^a, Kathleen S. Mahan ^b, Talia D. Wiggen ^c, Adam J. Gilbertsen ^c, Marshall I.
5 Hertz ^b, Ryan C. Hunter ^{c*} and Robert A. Quinn ^{a*}

6 ^a Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing,
7 Michigan, USA.

8 ^b Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine,
9 University of Minnesota, Minneapolis, Minnesota, USA.

10 ^c Department of Microbiology and Immunology, University of Minnesota Medical School,
11 Minneapolis, Minnesota, USA.

12 * Denotes co-corresponding authors: Ryan C. Hunter, Department of Microbiology and
13 Immunology, University of Minnesota Medical School, 689 23rd Ave SE, Minneapolis,
14 Minnesota, 55455, rchunter@umn.edu; Robert A. Quinn, 603 Wilson Rd. Rm 120, Department
15 of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan,
16 48824, quinnrob@msu.edu

17 18 **Abstract**

19 **Background** Progression of chronic lung disease often leads to the requirement for a lung
20 transplant (LTX). Despite improvements in short-term survival after LTX, chronic lung allograft
21 dysfunction (CLAD) remains a critical challenge for long-term survival. This study investigates
22 the relationship between the metabolome of bronchoalveolar lavage fluid (BALF) from subjects
23 post-LTX with underlying lung disease and CLAD severity.

24 **Methods** Untargeted LC-MS/MS metabolomics was performed on 960 BALF samples collected
25 over 10 years from LTX recipients with alpha-1-antitrypsin disease (AATD, n=22), cystic fibrosis
26 (CF, n=46), chronic obstructive pulmonary disease (COPD, n = 79) or pulmonary fibrosis (PF,
27 n=47). Datasets were analyzed using machine learning and multivariate statistics for
28 associations with underlying disease and final CLAD severity.

29 **Results.** BALF metabolomes varied by underlying disease state, with AATD LT recipients being
30 particularly distinctive (PERMANOVA, $p=0.001$). We also found a significant association with
31 the final CLAD severity score (PERMANOVA, $p=0.001$), especially those with underlying CF.
32 Association with CLAD severity was driven by changes in phosphoethanolamine (PE) and
33 phosphocholine lipids that increased and decreased, respectively, and metabolites from the
34 bacterial pathogen *Pseudomonas aeruginosa*. *P. aeruginosa* siderophores, quorum-sensing

35 quinolones, and phenazines were detected in BALF, and 4-hydroxy-2-heptylquinoline (HHQ)
36 was predictive of the final CLAD stage in samples from CF patients ($R=0.34$; $p\leq 0.01$).
37 Relationships between CLAD stage and *P. aeruginosa* metabolites were especially strong in
38 those with CF, where 61% of subjects had at least one of these metabolites in their first BALF
39 sample after transplant.

40 **Conclusions:** BALF metabolomes after LTX are distinctive based on the underlying disease
41 and reflect final CLAD stage. In those with more severe outcomes, there is a lipid transition from
42 PC to predominantly PE phospholipids. The association of *P. aeruginosa* metabolites with
43 CLAD stages in LTX recipients with CF indicates this bacterium and its metabolites may be
44 drivers of allograft dysfunction.

45

46 **Key messages:** Despite the high prevalence of CLAD among LTX recipients, its pathology is
47 not well understood, and no single molecular indicator is known to predict disease onset. Our
48 machine learning metabolomic-based approach allowed us to identify patterns associated with a
49 shift in the lipid metabolism and bacterial metabolites predicting CLAD onset in CF. This study
50 provides a better understanding about the progression of allograft dysfunction through the
51 molecular transitions within the transplanted lung from the host and bacterial pathogens.

52

53 **Key words** Metabolomics; cystic fibrosis; bronchioalveolar lavage fluids; chronic lung allograft
54 dysfunction, chronic lung diseases; phosphoethanolamine; phosphocholine; quinolones,
55 *Pseudomonas aeruginosa*.

56

57 **Word count:** 3,452

58

59

60

61 **Introduction**

62 Lung transplantation (LTX) is a therapeutic option for patients who develop progressive
63 and severe chronic lung disease [1]. However, chronic lung allograft dysfunction (CLAD)
64 remains a major barrier to long-term LTX patient survival, as it affects 50% of patients at five
65 years post-transplantation [2,3]. Bronchiolitis obliterans syndrome (BOS), a crucial phenotypic
66 manifestation of allograft dysfunction [4,5], is used as a scaled measure of disease progression
67 (i.e., CLAD stage) [6]. Notoriously a heterogenous disease, BOS severity scores were recently
68 updated in 2019 [6] to better characterize the stages of severity experienced by LTX recipients.
69 These CLAD stages can occur post-LTX in patients with different pre-LTX lung diseases such
70 as alpha-1-antitrypsin deficiency disease (AATD), cystic fibrosis (CF), chronic obstructive
71 pulmonary disease (COPD), and pulmonary fibrosis (PF) [7–10].

72 Bronchoalveolar lavage fluid (BALF) is a valuable sample type for studying pathological
73 characteristics that develop after LTX due to the direct proximity of BALF sample origin to the
74 site of stress and/or injury in the lung [11]. Metabolites detected within BALF can be indicative of
75 physiological processes of disease progression, microbial lung burden, and possibly, allograft
76 rejection [12,13]. However, there are few studies of BALF metabolomes describing the
77 composition, microbial virulence factors, amino acids, lipids, and a myriad of pharmaceuticals
78 [14–17].

79 Untargeted mass spectrometry (MS)-based metabolomics allows exploration of the
80 chemical diversity associated with a wide range of biological samples [18,19]. However,
81 navigating the diverse chemical data generated in untargeted metabolomics studies, in which a
82 large proportion of detectable metabolites are unknown, remains challenging [18,19]. Advances
83 in bioinformatic analyses of MS data have enabled a more comprehensive interpretation of
84 biological information contained within these highly technical and large datasets. For example,
85 the Global Natural Products Social molecular networking web platform (GNPS) has simplified
86 the exploration of the chemical space of metabolomes. GNPS is a tandem mass spectrometry
87 (MS/MS) automated data organizational tool that enables comparisons of MS/MS fragmentation
88 patterns among samples to cluster and visualize related molecules in a spectral network [20,21].
89 GNPS can be paired with metabolite feature quantification algorithms to create a
90 comprehensive workflow for untargeted metabolomics of clinical samples [20,22]. In this study,
91 we applied this approach to 960 BALF samples collected longitudinally from 194 LTX recipients
92 to determine whether post-transplant BALF metabolomes reflect the underlying disease
93 diagnosis; and whether specific molecular signatures correlate with allograft dysfunction.

94

95 **Materials and Methods**

96 **Study Design, Subjects, and BOS-Grading.**

97 Subjects with AATD, CF, COPD, and IPF who underwent lung transplantation at the
98 University of Minnesota consented to have a portion of their post-LTX BALF used for research.
99 BALF was collected over a 10-year period from 2002 to 2012 as a routine procedure per
100 transplant protocol or if undergoing diagnostic BALF collection due to clinical indications, such
101 as new radiographical changes, new respiratory symptoms, or a decrease in FEV₁. Inclusion
102 criteria were ≥ 18 years of age; diagnosis of AATD, CF, COPD, or PF; and receipt of a bilateral
103 or single lung transplant. Exclusion criteria were < 18 years of age and the inability to provide
104 consent and/or tolerate the BALF procedure. Clinical characteristics of subjects in this study,
105 including disease progression scores and samples collected for each, are displayed in Table 1
106 and Table S1. BOS-grade was recorded for patients based on the changes in their forced
107 expiratory volume in one second (FEV₁), initially determined using definitions of the International
108 Society for Heart and Lung Transplantation (ISHLT) [23], and updated here to reflect current
109 CLAD definitions [6]. The final CLAD stage was known for each patient, while some measures
110 were determined after sample collection ceased. This protocol was approved by the University
111 of Minnesota IRB (STUDY00004547).

112

113 **Bronchoalveolar lavage sampling material.**

114 Bronchoalveolar lavage fluid (BALF) was collected via orotracheal or nasotracheal
115 bronchoscopy. Sterile saline was instilled into a subsegmental bronchus after advancement and
116 occlusion of the airway lumen. BALF was separated into ~1.5 mL aliquots and frozen at -80 °C
117 for further untargeted metabolomic analysis (see supplementary methods). All 960 samples
118 were included for analysis of variation (ANOVA) among underlying disease types and
119 associations with final CLAD stages.

120

121 **Organic extraction and LC-MS/MS analysis**

122 Methanolic extracts of 960 BALF samples (50:50 v/v) were analyzed on a Thermo
123 QExactive™ mass spectrometer coupled to a Vanquish Ultra-High-Performance Liquid
124 Chromatography (UHPLC) system (ThermoFisher) (see supplementary methods) [21,24].
125 Subsequently, feature-based molecular networking (FBMN) was performed with a parent and
126 fragment mass ion tolerance of 0.02 Da, a cosine score of 0.65, and a minimum matched peaks
127 minimum of 4 [22]. FBMN is publicly available at
128 <https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=756456ac794d48b0bba80dbe28e0de66>,

129 and raw data files are available in the MASSIVE data repository as [MSV000085760](https://massive.ucsf.edu/MSV000085760). Data
130 curation consisted of removing metabolites detected in blanks and removal of known
131 pharmaceuticals and their related nodes in the molecular network (see supplementary methods,
132 Figure S1, and Table S2). Presence/absence frequency and rank abundance of all molecular
133 features were calculated after creating a cutoff by summing the relative abundances of features
134 above 10×10^5 abundance in samples obtained from subjects with AATD, CF, COPD, or IPF.

135

136 **Statistical analysis**

137 Variations in metabolomic data associated with underlying disease type and the final
138 CLAD stage for each subject were assessed using beta-diversity metrics and tested for
139 significance with permutational multivariate analysis of variance (PERMANOVA). Metabolome
140 variation was further assessed using random forest (RF) classification and regression analysis
141 (numerical CLAD stages, 0 to 4). A Bray-Curtis dissimilarity matrix was calculated on the entire
142 metabolome and used to generate principal coordinate analysis (PCoA) plots through the in-
143 house tool ClusterApp and visualized in EMPeror [25]. PERMANOVA tests were performed for
144 diseases and CLAD stages (as a categorical variable) with subject-source as an interacting
145 factor to account for variation in the number of samples per subject. Post-hoc tests among
146 disease types were performed with R packages Devtools and Vegan (pairwise-adonis) [26,27].
147 Variable importance plots from both RF approaches were used to identify metabolites driving
148 the variation observed. Pearson correlations were used to determine relationships between
149 metabolite abundance and final CLAD stages, as well as the correlation of *P. aeruginosa*
150 metabolites with its relative abundance determined using 16S rRNA sequence data from the
151 same samples. 16S rRNA sequence data were generated using bacterial genomic DNA
152 extracted from each sample, sequencing the V4 region using Illumina MiSeq TruSeq 2x300
153 paired-end technology, and sequence analysis in R as previously described [28]. The relative
154 abundance of *P. aeruginosa* was determined using DADA2 [29]. R packages random forest,
155 vegan and ggplot2 were also used for these analyses [30–32] (see supplementary methods).

156

157 **Results**

158 **Sample collection and clinical design.**

159 The two primary objectives for this study were: i) to determine if the metabolome of
160 BALF collected after LTX was associated with the underlying pre-LTX lung diagnosis, and ii) if
161 the data were associated with measures of CLAD severity across all subjects and within each
162 underlying disease type. The dataset comprised longitudinal BALF samples (n = 960) collected

163 over a 10-year period from subjects ($n = 194$) with one of four underlying conditions prior to
164 transplant; AATD ($n = 22$), CF ($n = 46$), COPD ($n = 79$), and PF ($n = 47$). Clinical parameters
165 and patient demographic information are presented in Table 1. Subjects developed CLAD at
166 different times and to varying degrees during the collection period. The final BOS-grade of all
167 subjects was known, even when this measure was recorded after BALF collection had ceased.
168 Thus, metabolome data variation was tested against this final BOS-grade measure.

169

170 **BALF metabolome variation based on the underlying lung disease type pre-transplant**

171 Since BALF samples were obtained via bronchoscopy, numerous drugs and xenobiotics
172 were identified in the dataset. We reasoned that these molecules could confound underlying
173 biologically significant trends, so they were removed from the metabolome data using Global
174 Natural Product Social (GNPS) library searching and molecular networking to identify known
175 and chemically related pharmaceuticals in the GNPS libraries. After filtering pharmaceuticals
176 and sample contaminants (detected in controls), the entire BALF data set included 4755
177 molecular features, of which 361 had a spectral match to known compounds in GNPS libraries
178 [21].

179 PCoA ordination of the entire dataset, colored by pre-transplant disease diagnosis,
180 revealed significant differences between AATD, CF, COPD, and PF cohorts (PERMANOVA $F =$
181 3.91 , $p = 0.001$, Figure 1a). Additionally, post-hoc testing showed significant pairwise
182 differences between diseases (Table 2), suggesting that allograft metabolomes are dependent,
183 in part, on the underlying disease of the transplant recipient. This unique disease signature was
184 especially marked in subjects with AATD, as evidenced by its low random forest (RF)
185 classification error (13.3%, Table S3) and separation by PCoA clustering (Figure 1a). We then
186 used supervised RF classification analysis to identify metabolites that most strongly
187 distinguished BALF samples by the underlying disease. The top 10 metabolites driving
188 differences between groups included phenylalanine, phosphocholines, and other lipids. Notably,
189 phenylalanine was particularly abundant in subjects with underlying AATD (pairwise p-value CF
190 $p = 2.9 \times 10^{-11}$, COPD $p = 4.7 \times 10^{-14}$, and IPF $p = 3.1 \times 10^{-13}$) (Figure 1b, Figure S2).

191 To further understand the nature of the unique BALF metabolome in LTX recipients with
192 AATD, we analyzed metabolite presence/absence to determine the degree of chemical sharing
193 among underlying diseases. Although most metabolites were shared across all four diseases,
194 AATD unexpectedly had fewer molecules shared with the other diseases (either one other, or
195 two others, Figure 1c). Rank abundance curves of the metabolome revealed that AATD had

196 fewer overall metabolites, and these were less abundant than the other three disease types
197 (Figure 1a,d).

198

199 **Longitudinal allograft metabolomes are associated with CLAD severity outcomes**

200 Each subject's final CLAD stage was then used to assess the relationship between the
201 entire longitudinal metabolome dataset and disease severity (n = 960). PERMANOVA
202 (categorical CLAD stage, F = 4.023, p = 0.001) and RF regression (linearized CLAD stage,
203 variance explained = 11.08%) revealed an overall association of the final CLAD stage with
204 collective longitudinal metabolome composition (Figure 2a). When tested separately on each
205 pre-LTX disease diagnosis, CLAD stages maintained their categorical significance for all but IPF
206 (Figure 2b). RF regression showed that LTX recipients with underlying CF had the strongest
207 association of their BALF metabolome variation with numerical CLAD stages (% variance
208 explained = 34.04), followed by COPD (14.36) and markedly less variation in IPF (4.65) and
209 AATD (3.16) (Figure S3). These results demonstrate a significant relationship between the
210 BALF metabolome after LTX and the final CLAD stage, which was particularly strong among
211 individuals with CF.

212

213 **Altered phospholipids and *P. aeruginosa*-derived molecules drive association with the** 214 **final CLAD stage**

215 The association between CLAD stage and longitudinal metabolome composition,
216 particularly among CF subjects, motivated further analyses of specific metabolites that most
217 strongly influenced trends in the dataset. Variable importance plots from the RF analysis of the
218 entire dataset and each disease analyzed separately revealed several metabolites of interest
219 (Figure S3, S4). Molecular networking was then used to help annotate and identify these and
220 related molecules. With this approach, we identified four clusters ('molecular families') of
221 interest, including phosphoethanolamine (molecular family I), phosphocholine (molecular
222 families II and III), and quinolone-like-molecules (molecular family IV, Figure S5). The molecular
223 family I included the phospholipids lysophosphoethanolamine (lysoPE) 18:0/0:0 (*m/z* 482.3225
224 [M+H]⁺, C₂₃H₄₉NO₇P, 3.4 ppm error) and lysoPE 18:1/0:0 (*m/z* 480.3073 [M+H]⁺, C₂₃H₄₇NO₇P,
225 2.40 ppm error). Molecular family II included phosphatidylcholine 16:0/14:0 (*m/z* 728.5183
226 [M+Na]⁺, C₃₈H₇₆NO₈P, 2.42 ppm error). Molecular family III corresponds to PC 16:0/18:0 (*m/z*
227 780.5529 [M+Na]⁺, C₄₂H₈₀NO₈P -2.20 ppm error). Finally, in molecular family IV, we identified 4-
228 hydroxy-2-heptylquinolone (HHQ, *m/z* 244.1689 [M+H]⁺, C₁₆H₂₂NO 2.8 ppm error), a
229 *Pseudomonas aeruginosa*-derived quinolone and known quorum sensing metabolite that plays

230 an integral role in the gene expression and physiology of this opportunistic pathogen (Figures
231 S5 and S6) [33].

232 We then plotted the relationship between the feature abundances of each metabolite of
233 interest with the final CLAD stages across the entire dataset. Both lysoPE(18:0/0:0) and
234 lysoPE(18:1/0:0) significantly increased with disease progression (Pearson $r = 0.23$, $p = 6.9e-13$
235 , and $r = 0.16$, $p = 0.017$, respectively). In contrast, phosphocholine molecules PC (16:0/14:0)
236 and PC(16:0/18:0) decreased as final disease severity increased (Pearson $r = -0.22$, $p = 4.4e-$
237 10 and $r = -0.19$, $p = 1.9e-08$, respectively). Linear regression analysis of HHQ abundance and
238 individual subjects' final CLAD stage also showed a significant increase as allograft dysfunction
239 worsened (Pearson $r = 0.14$, $p = 0.0035$) (Figure 3a).

240 Finally, we parsed the molecular dynamics of these molecules based on the underlying
241 disease and identified unique trends within each condition. LysoPE (18:0/0:0) significantly
242 increased with disease progression in CF (Pearson $r = 0.33$, $p \leq 0.001$), followed by COPD ($r =$
243 0.28 , $p \leq 0.001$) and IPF ($r = 0.14$ $p \leq 0.001$), but not in AATD. LysoPE (18:1/0:0) abundance
244 was positively correlated with IPF only (Pearson $r = 0.42$, $p \leq 0.001$). The feature abundance of
245 PC (16:0/14:0) significantly decreased as disease severity worsened only in CF and COPD
246 (Pearson $r = -0.41$, $p \leq 0.001$ and $r = -0.28$ $p \leq 0.001$, respectively), whereas PC (16:0/18:0)
247 significantly decreased in CF, COPD and IPF (Pearson $r = -0.27$, $p \leq 0.001$; $r = -0.24$, $p \leq 0.001$;
248 and $r = -0.19$ $p \leq 0.001$, respectively). Neither of these molecules varied with CLAD stages in
249 AATD. In the case of HHQ, its molecular abundance significantly increased with disease
250 progression in CF (Pearson $r = 0.34$, $p \leq 0.001$) (Figure 3b) but not the others, indicating that
251 the trend seen in the complete dataset was driven by the CF samples.

252

253 ***Pseudomonas aeruginosa* molecular signatures in subjects with CF after LTX**

254 The association of HHQ with CLAD severity led to further analysis of the diversity of *P.*
255 *aeruginosa* metabolites and their relationship with clinical outcomes, particularly in those
256 subjects with CF. Molecular networking allowed us to identify additional molecular signatures
257 from the pathogen, including 2-heptyl-4-quinolone-N-oxide (HQNO; m/z 260.1645 [M+H]⁺,
258 C₁₆H₂₂NO₂; 10.67 ppm), 2-nonyl-4-quinolone (HNQ; m/z 270.1852 [M+H]⁺, C₁₇H₂₄NO; 7.45
259 ppm), pyocyanin (m/z 211.0866 [M+H]⁺, C₁₃H₁₁N₂O; 5.64 ppm) and pyochelin (m/z 325.0675
260 [M+H]⁺, C₁₄H₁₆N₂O₃S₂; 10.46 ppm). Molecular network node mapping based on disease showed
261 that the entire molecular family of quinolones and pyochelin were enriched in subjects with
262 underlying CF (pie charts within nodes) (Figure 4a). We were therefore interested in determining
263 when these molecules were detected in the longitudinal BALF samples of each subject. We

264 found that ~60% of samples (n = 46) from subjects with CF were positive for at least one *P.*
265 *aeruginosa* molecule in the first BALF sample collected (Figure 4b), and the abundances were
266 particularly high at this first-time point (Figure 4c). This proportion of positive samples stayed
267 relatively stable, with a slight decrease in successive BALFs collected (Figure 4b). Some
268 subjects showed acquisition of *P. aeruginosa* molecules as time since transplant progressed,
269 whereas most initially had high abundances and a subsequent decrease (Figure 4c). However,
270 a Pearson correlation between the abundance of these molecules and the time since LTX was
271 not significant (R = 0.074; p = 0.18). The abundance of these molecules did increase (R = 0.34;
272 p = 0.0046) with the relative abundance of *Pseudomonas* sp. (Figure 4d,e).

273

274 Discussion

275 In this study, we applied untargeted metabolomics to 960 BALF samples from patients
276 who had undergone LTX for chronic lung disease. We had a particular interest in metabolite
277 variation based on the underlying disease and the “gold standard” measure of disease severity
278 (i.e., CLAD stage). The post-LTX metabolome data differed based on the underlying disease,
279 with the unique profile found in AATD. Other chronic lung diseases (CF, COPD, PF) were
280 significantly different from one another but more difficult to distinguish overall. The uniqueness
281 of AATD was driven by differences in aromatic amino acids (phenylalanine), an overall lack of
282 shared molecules with the other diseases, and a lower abundance of metabolite features
283 overall. We note that all four underlying conditions have unique etiologies, and the findings here
284 indicate that, somewhat unexpectedly, the chemical environment of the lung allograft reflects
285 the initial disease of the recipient, particularly in the case of AATD. The high abundance of
286 phenylalanine in allografts from subjects with AATD may reflect increased proteolysis, which is
287 a hallmark of this disease [23], though further research is needed to confirm this hypothesis.

288 The overall annotation rate of MS/MS spectra in our dataset was 7.6%, which is not
289 uncommon in untargeted metabolomics studies [34]. Low levels of metabolite identification are a
290 known challenge in metabolomics and can limit the ability to infer mechanistic associations with
291 disease severity, although annotation rates in untargeted metabolomics experiments are
292 increasing as new search algorithms and databases become available [22,35–37].
293 Nevertheless, there is considerable power in using comprehensive molecular data from
294 untargeted metabolomics experiments to identify biological trends, even when the molecular
295 structures are not known. An important step for this approach, which we performed here, is the
296 removal of pharmaceuticals and xenobiotics, which can be highly abundant and overwhelm
297 underlying biological signals. The molecular networking algorithm applied here greatly increases

298 the ability to ‘clean up’ the metabolome by enabling the identification and visualization of
299 pharmaceuticals and their chemical relatives.

300 Bronchoalveolar lavage fluids have been used recently for describing molecular changes
301 in lipids and metabolites after LTX [16]; however, the association of these compounds with
302 allograft dysfunction has not been addressed. One of the strongest signatures in our
303 metabolomic data was the association of the metabolome with the final CLAD stage of each
304 subject, and this was particularly strong for those with CF. In this case, many of the molecular
305 features driving the association had annotations in the GNPS libraries, and they were primarily
306 phospholipids and bacterial metabolites. A closer analysis of these molecules identified a
307 transition in lipid species associated with an increased final CLAD stage. Subjects whose final
308 CLAD severity was lower had more abundant phosphocholine lipids in their longitudinal BALF
309 metabolome, while those with more severe CLAD outcomes had a higher abundance of
310 phosphoethanolamine lipids. This phospholipid lipid transition may indicate a disruption in
311 airway surface liquid (ASL) in the transplanted lung as the disease progresses or alterations in
312 lipid metabolism. ASL is mainly composed of phospholipids (90%) and proteins (10%), which
313 are products of surface and submucosal gland epithelia and resident phagocytic cells [38].
314 Approximately 70–80% of ASL lipids are dipalmitoyl phosphatidylcholine (DPPC) [39,40] and PE
315 is a major phospholipid in lung surfactant. The increase in PE abundance associated with CLAD
316 severity found here may be due to the influx of neutrophils or other inflammatory cells containing
317 this lipid. Another potential source is allograft-colonizing microbiota, as PE lipids are known to
318 be a component of bacterial membranes [41,42].

319 Detection of quorum-sensing metabolites from *P. aeruginosa* in BALF and the
320 association of HHQ with final CLAD severity implicates the bacterium and its metabolism in
321 disease progression. These molecules were particularly prevalent in subjects with underlying
322 CF, where this bacterium is a known opportunistic pathogen responsible for chronic airway
323 infection [43–45] [43]. *P. aeruginosa* regulates the production of its virulence factors through its
324 quorum sensing system, which plays an important role in CF pathogenesis. Multiple quinolones
325 from *P. aeruginosa* such as HQNO, HNQ, and PQS (Pseudomonas quinolone signal), were
326 detected in BALF, as were other two other small molecule virulence factors pyocyanin and
327 pyochelin. Quorum sensing is mediated through N-acyl-homoserine lactones (AHLs) and alkyl
328 quinolones (AQ) [46], the latter of which were detected in this study. The correlation between
329 the abundance of these molecules and the final CLAD stage indicates they could potentially be
330 explored as biomarkers of bacterial infection in CF patients post-LTX and as indicators of CLAD
331 progression. Furthermore, they are relatively easy to detect with LC-MS/MS rapidly after sample

332 extraction. Finally, we note that many of these *P. aeruginosa* small molecules were detected in
333 the first BALF sample after LTX. This observation supports the hypothesis that the bacterium
334 readily re-colonizes the respiratory tract post-LTX from its reservoir in the upper airways (i.e.,
335 paranasal sinuses) [44]. Though data from this study cannot directly assess this infection
336 reservoir, the detection of quinolones in BALF so early after LTX is an important finding for
337 understanding the pathogenesis of CLAD.

338

339 **Conclusions**

340 The BALF metabolome after lung transplant revealed differences based on underlying lung
341 disease type and association with final CLAD severity. An important metabolic trend was a shift
342 in the relative abundance of phosphocholine and phosphoethanolamine lipids that were
343 predictive of a subject's final CLAD stages with CF. These findings indicate potential predictive
344 value for the lipid profile as an indicator of disrupted airway surface liquid and impending CLAD
345 severity. Importantly, our LC-MS/MS approach readily detected virulence metabolites from the
346 bacterial pathogen *P. aeruginosa*, especially in CF samples, which were associated with poor
347 CLAD outcomes. This study provides a picture of the molecular transitions within the
348 transplanted lung from the host and bacterial pathogens that may help understand the
349 progression of allograft dysfunction and merits further study with more targeted approaches for
350 the molecules identified.

351 **Acknowledgment**

352 We thank Anthony Schillmiller for his constant support during sample processing in the mass
353 spectrometry and metabolomics core laboratory at Michigan State University. The CF
354 Foundation grant HUNTER18ABO and the National Institute of Allergy and Infectious Diseases
355 (R01AI145925) provided funding.

356 **Author contributions:**

357 R. Hunter and R. Quinn conceptualized the study. K. Mahan performed BALF/CLAD stages
358 tabulation. C. Martin, T. Wiggen, and R. Quinn performed data acquisition, analysis, and
359 interpretation. C. Martin, R. Quinn, and R. Hunter wrote the original and final versions of the
360 manuscript. K. Mahan and M. Hertz edited the manuscript. All authors read and approved the
361 final manuscript.

362 **Disclosure statement:**

363 All authors in the presented manuscript have no conflicts of interest to disclose.

364 **Sources of funding:**

365 Cystic Fibrosis Foundation (HUNTER18ABO) and National Institutes of Health (R01AI145925).

366

Clinical parameters	AATD	CF	COPD	IPF
<i>Number of subjects</i>	22	46	79	47
<i>Sex ratio (F/M)</i>	0.69 (9/13)	1.20 (25/21)	1.20 (43/36)	0.42 (14/33)
<i>Average of age at LTX (range)</i>	55 (42 – 55)	36 (20 – 54)	59 (44 – 74)	58 (39 – 68)
<i>Average of last recorded FEV₁ (range)</i>	64 (18 - 96)	69 (17 – 100)	65 (23 – 100)	68 (26 – 99)
<i>Average of last recorded CLAD stage (0 to 4)</i>	1.57	1.35	1.62	1.36
<i>Number of subjects with P. aeruginosa (%)</i>	11 (50%)	32 (70%)	7 (5%)	4 (9%)
<i>BALF samples</i>	130	185	362	283
<i>BALF average/subject (range)</i>	5.01 (2-12)	4.02 (1-9)	4.58 (2-9)	6.02 (3-10)
<i>Average of sample collection (years)</i>	2.93	3.33	3.64	4.05

367

368 **Table 1.** Clinical characteristics of subjects (total n=194) and samples (total n=960) collected
 369 post-LTX grouped by prior underlying disease – alpha-1 anti-trypsin deficiency (AATD), cystic
 370 fibrosis (CF), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis
 371 (IPF). BALF sampling information, microbiology associated with *Pseudomonas aeruginosa*, age
 372 at transplant (LTX), sex ratio (female/male). The averages of the last recorded forced expiratory
 373 volume per 1 second expressed as a percent of predicted (%FEV₁) and the CLAD stage are
 374 displayed based on pre-transplant diagnoses.

375

376


377

Pairwise Comparisons	F-value	p-value
COPD and IPF	26.5689	0.001
COPD and CF	2.1869	0.002
COPD and IPF	1.7698	0.017
AATD and CF	21.2079	0.001
AATD and IPF	28.6926	0.001
CF and IPF	3.1142	0.001

378 **Table 2** Post-hoc pairwise comparisons of BALF metabolome among different diseases (AATD,
379 CF, COPD, and IPF).

380


381



382


383 **Figure 1. Lung allograft metabolomic profiles vary by pre-LTX condition.** a) PCoA plot of a
384 Bray-Curtis distance matrix of lung allograft BALF metabolomic profiles. Samples colored by
385 pre-LTX disease and demonstrate significant differences among disease types (PERMANOVA,
386 $F=3.91$, $p = 0.001$, random forest out-of-bag (OOB) error = 41.03%). b) Feature abundance of
387 DL-Phenylalanine by disease state. Kruskal-Wallis test and post-hoc Dunn test p-values are
388 shown. c) Uniqueness and sharing of BALF metabolites across diseases. Molecule presence or
389 absence was determined and plotted by the number of molecules that are unique, shared with
390 one other, two others, or all four diseases. d) Ranking molecular abundance curves of BALF
391 metabolome colored by disease.

392




393

394 **Figure 2.** Principal coordinate analysis plots of Bray-Curtis distance matrices calculated for
395 BALF metabolome based on CLAD stage measurements: Statistics from the categorical
396 PERMANOVA testing (F and p-value) and linear variation based on the RF analysis (%Var) are
397 shown for each plot. a) PCoA plot of the entire BALF metabolome colored by the final CLAD
398 stages. b) PCoA plots of the entire BALF metabolomic data separated by disease type colored
399 by the final CLAD stages.



400
 401 **Figure 3** a) Scatter plots and linear regression analysis of feature abundances of target
 402 molecules lysoPE (18:0/0:0), lysoPE (18:1/0:0), PC (16:0/14:0), PC(16:0/18:0), and HHQ for all
 403 diseases against the final BOS-grade. Statistics of the linear regression are shown on the plots.
 404 b) Box plots of feature abundances of each molecule with final CLAD stages separated by
 405 individual diseases (AATD, CF, COPD, IPF). Pearson correlation test (R) is displayed, and *** =
 406 p values ≤ 0.001 .

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



Quinolones nomenclature






HQNO: 2-heptyl-4-quinolone-N-oxide
HNQ: 2-nonyl-4-quinolone
HHQ: 4-hydroxy-2-heptylquinolone

Color information in sub-networks

Pie chart colors represents feature abundance based on diseases

AATD CF COPD IPF

Annotated by GNPS: Edge width represent spectral similarity between nodes (cosine score) | 0.70 - 1.00 |



408
409 Figure 4. *Pseudomonas*-derived molecules in subjects that underwent lung transplant due to CF
410 disease. A) Molecular networks of microbial molecules produced by *Pseudomonas* sp. that were
411 identified by GNPS library searching. Each node represents a unique MS/MS spectrum
412 (putative molecule), and connections between nodes are determined by spectral similarity

413 (cosine score) from MS/MS alignment. Pie charts represent total feature abundance colored by
414 the underlying disease. B) Percentage of samples that displayed *Pseudomonas*-like molecules
415 in subjects with CF across longitudinal BALF sampling time points and C) dynamics among
416 subjects over time. D) Linear correlation plot displaying the abundance of selected
417 *Pseudomonas* molecules post-LTX and E) its relation to *Pseudomonas spp.* relative abundance
418 in samples.
419





420 **References**

- 421 1 Afonso JE, Júnior, de Campos Werebe E, *et al.* Lung transplantation. *Einstein*
422 2015;**13**:297.
- 423 2 Yusen RD. Technology and Outcomes Assessment in Lung Transplantation. Proceedings
424 of the American Thoracic Society. 2009;**6**:128–36. doi:10.1513/pats.200809-102go
- 425 3 Chambers DC, Cherikh WS, Goldfarb SB, *et al.* The International Thoracic Organ
426 Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-
427 fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan
428 Transplantation. *J Heart Lung Transplant* 2018;**37**:1169–83.
- 429 4 Tissot A, Danger R, Claustre J, *et al.* Early Identification of Chronic Lung Allograft
430 Dysfunction: The Need of Biomarkers. *Front Immunol* 2019;**10**.
431 doi:10.3389/fimmu.2019.01681
- 432 5 DerHovanesian A, Wallace WD, Lynch JP 3rd, *et al.* Chronic Lung Allograft Dysfunction:
433 Evolving Concepts and Therapies. *Semin Respir Crit Care Med* 2018;**39**:155–71.
- 434 6 Verleden GM, Glanville AR, Lease ED, *et al.* Chronic lung allograft dysfunction: Definition,
435 diagnostic criteria, and approaches to treatment- A consensus report from the Pulmonary
436 Council of the ISHLT. *J Heart Lung Transplant* 2019;**38**:493–503.
- 437 7 Conrad A, Janciauskiene S, Köhnelein T, *et al.* Impact of alpha 1-antitrypsin deficiency and
438 prior augmentation therapy on patients' survival after lung transplantation. *Eur Respir J*
439 2017;**50**. doi:10.1183/13993003.00962-2017
- 440 8 Kneidinger N, Milger K, Janitza S, *et al.* Lung volumes predict survival in patients with
441 chronic lung allograft dysfunction. *Eur Respir J* 2017;**49**. doi:10.1183/13993003.01315-
442 2016
- 443 9 Fernandez IE, Heinzelmann K, Verleden S, *et al.* Characteristic patterns in the fibrotic lung.
444 Comparing idiopathic pulmonary fibrosis with chronic lung allograft dysfunction. *Ann Am*
445 *Thorac Soc* 2015;**12 Suppl 1**:S34–41.
- 446 10 Joshua Blatter SS. Lung Transplantation in Cystic Fibrosis: Trends and Controversies.
447 *Pediatr Allergy Immunol Pulmonol* 2015;**28**:237.
- 448 11 Walmsley S, Cruickshank-Quinn C, Quinn K, *et al.* A prototypic small molecule database for
449 bronchoalveolar lavage-based metabolomics. *Sci Data* 2018;**5**:180060.
- 450 12 Das S, Bernasconi E, Koutsokera A, *et al.* A prevalent and culturable microbiota links
451 ecological balance to clinical stability of the human lung after transplantation. *Nat Commun*
452 2021;**12**:2126.
- 453 13 Combs MP, Wheeler DS, Luth JE, *et al.* Lung microbiota predict chronic rejection in healthy


- 454 lung transplant recipients: a prospective cohort study. *Lancet Respir Med* 2021;**9**:601–12.
- 455 14 Evans CR, Karnovsky A, Kovach MA, *et al.* Untargeted LC-MS metabolomics of
456 bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health.
457 *J Proteome Res* 2014;**13**:640–9.
- 458 15 Cribbs SK, Park Y, Guidot DM, *et al.* Metabolomics of bronchoalveolar lavage differentiate
459 healthy HIV-1-infected subjects from controls. *AIDS Res Hum Retroviruses* 2014;**30**:579–
460 85.
- 461 16 Watzenboeck ML, Gorki A-D, Quattrone F, *et al.* Multi-omics profiling predicts allograft
462 function after lung transplantation. *Eur Respir J* 2022;**59**. doi:10.1183/13993003.03292-
463 2020
- 464 17 Walter S, Gudowius P, Bosshammer J, *et al.* Epidemiology of chronic *Pseudomonas*
465 *aeruginosa* infections in the airways of lung transplant recipients with cystic fibrosis. *Thorax*
466 1997;**52**:318–21.
- 467 18 da Silva RR, Lopes NP, Silva DB. CHAPTER 3:Metabolomics. In: *Mass Spectrometry in*
468 *Chemical Biology*. 2017. 57–81.
- 469 19 Garg N, Kapon C, Lim YW, *et al.* Mass spectral similarity for untargeted metabolomics
470 data analysis of complex mixtures. *Int J Mass Spectrom* 2015;**377**:719–717.
- 471 20 Quinn RA, Nothias L-F, Vining O, *et al.* Molecular Networking As a Drug Discovery, Drug
472 Metabolism, and Precision Medicine Strategy. *Trends Pharmacol Sci* 2017;**38**:143–54.
- 473 21 Wang M, Carver JJ, Phelan VV, *et al.* Sharing and community curation of mass
474 spectrometry data with Global Natural Products Social Molecular Networking. *Nat*
475 *Biotechnol* 2016;**34**:828–37.
- 476 22 Nothias L-F, Petras D, Schmid R, *et al.* Feature-based molecular networking in the GNPS
477 analysis environment. *Nat Methods* 2020;**17**:905–8.
- 478 23 Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. *Am J Respir*
479 *Crit Care Med* 2002;**166**:440–4.
- 480 24 Pluskal T, Castillo S, Villar-Briones A, *et al.* MZmine 2: modular framework for processing,
481 visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC*
482 *Bioinformatics* 2010;**11**:395.
- 483 25 Vázquez-Baeza Y, Pirrung M, Gonzalez A, *et al.* EMPeror: a tool for visualizing high-
484 throughput microbial community data. *Gigascience* 2013;**2**:16.
- 485 26 Wickham H, Hester J, Chang W. Devtools: Tools to make developing r packages easier. *R*
486 *package version*
- 487 27 Oksanen J, Kindt R, Legendre P, *et al.* The vegan package. *Community ecology package*

- 488 2007;**10**:719.
- 489 28 Lucas SK, Villarreal AR, Ahmad MM, *et al.* Anaerobic Microbiota Derived from the Upper
490 Airways Impact Staphylococcus aureus Physiology. *Infect Immun* 2021;**89**:e0015321.
- 491 29 Callahan BJ, McMurdie PJ, Rosen MJ, *et al.* DADA2: High-resolution sample inference
492 from Illumina amplicon data. *Nat Methods* 2016;**13**:581–3.
- 493 30 Raghuvanshi R, Vasco K, Vázquez-Baeza Y, *et al.* High-Resolution Longitudinal Dynamics
494 of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy.
495 *mSystems* 2020;**5**. doi:10.1128/mSystems.00292-20
- 496 31 Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer 2016.
- 497 32 Oksanen J, Blanchet FG, Kindt R, *et al.* Vegan: community ecology package. R package
498 version 1.17-4. <http://cran.r-project.org>> Acesso em 2010;**23**:2010.
- 499 33 Barr HL, Halliday N, Cámara M, *et al.* Pseudomonas aeruginosa quorum sensing
500 molecules correlate with clinical status in cystic fibrosis. *Eur Respir J* 2015;**46**:1046.
- 501 34 da Silva RR, Dorrestein PC, Quinn RA. Illuminating the dark matter in metabolomics. *Proc.*
502 *Natl. Acad. Sci. U. S. A.* 2015;**112**:12549–50.
- 503 35 Hoffmann MA, Nothias L-F, Ludwig M, *et al.* High-confidence structural annotation of
504 metabolites absent from spectral libraries. *Nat Biotechnol* 2022;**40**:411–21.
- 505 36 Jarmusch AK, Wang M, Aceves CM, *et al.* ReDU: a framework to find and reanalyze public
506 mass spectrometry data. *Nat Methods* 2020;**17**:901–4.
- 507 37 Ernst M, Kang KB, Caraballo-Rodríguez AM, *et al.* MolNetEnhancer: Enhanced Molecular
508 Networks by Integrating Metabolome Mining and Annotation Tools. *Metabolites* 2019;**9**.
509 doi:10.3390/metabo9070144
- 510 38 Berkebile AR, McCray PB, Jr. Effects of airway surface liquid pH on host defense in cystic
511 fibrosis. *Int J Biochem Cell Biol* 2014;**52**:124.
- 512 39 Nkadi PO, Allen Merritt T, Pillers D-AM. An overview of pulmonary surfactant in the
513 neonate: Genetics, metabolism, and the role of surfactant in health and disease. *Molecular*
514 *Genetics and Metabolism*. 2009;**97**:95–101. doi:10.1016/j.ymgme.2009.01.015
- 515 40 Chen Z, Zhong M, Luo Y, *et al.* Determination of rheology and surface tension of airway
516 surface liquid: a review of clinical relevance and measurement techniques. *Respir Res*
517 2019;**20**:1–14.
- 518 41 Anandan A, Evans GL, Condic-Jurkic K, *et al.* Structure of a lipid A phosphoethanolamine
519 transferase suggests how conformational changes govern substrate binding. *Proc Natl*
520 *Acad Sci U S A* 2017;**114**:2218.
- 521 42 Sohlenkamp C, Geiger O. Bacterial membrane lipids: diversity in structures and pathways.


- 522 *FEMS Microbiol Rev* 2016;**40**:133–59.
- 523 43 Smith EE, Buckley DG, Wu Z, *et al.* Genetic adaptation by *Pseudomonas aeruginosa* to the
524 airways of cystic fibrosis patients. *Proc Natl Acad Sci U S A* 2006;**103**.
525 doi:10.1073/pnas.0602138103
- 526 44 Syed SA, Whelan FJ, Waddell B, *et al.* Reemergence of Lower-Airway Microbiota in Lung
527 Transplant Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 2016;**13**:2132–42.
- 528 45 McCort M, MacKenzie E, Pursell K, *et al.* Bacterial infections in lung transplantation. *J*
529 *Thorac Dis* 2021;**13**:6654–72.
- 530 46 Migiyama Y, Kaneko Y, Yanagihara K, *et al.* Efficacy of AiiM, an N-acylhomoserine
531 lactonase, against *Pseudomonas aeruginosa* in a mouse model of acute pneumonia.
532 *Antimicrob Agents Chemother* 2013;**57**. doi:10.1128/AAC.00456-13
533



a)




b)




It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).


A)



B)



A)



Quinolones nomenclature

HQNO: 2-heptyl-4-quinolone-N-oxide
HNQ: 2-nonyl-4-quinolone
HHQ: 4-hydroxy-2-heptylquinolone


Color information in sub-networks

Pie chart colors represents feature abundance based on diseases


■ AATD ■ CF ■ COPD ■ IPF

Annotated by GNPS: ● Edge width represent spectral similarity between nodes (cosine score) | 0.70 - 1.00 |


B)




C)



D)



E)



Patient ID

